Au5800 automatic biochemical analysis system

Demographic data of the enrolled pregnant women were obtained by an interview during the 11^th-13^th weeks of gestation, including age, nationality, body weight, blood pressure and disease history. Fasting blood was collected simultaneously for the detection of TSH, FT3 and FT4. Cord blood was collected during birth-giving. Heparinized plasma was obtained by centrifuge of the collected blood samples at 3000 rpm for 5 min, aliquoted and stored in a -86℃ deep freezer. Thyroid hormones and anti-TPO antibodies were measured with the fasting plasma collected during the 11^th-13^th weeks of gestation by a Cobas 6000 analyzer (Roche Diagnostics, Basil Switzerland) utilizing the electrochemiluminescence (ECL) technology. The levels of anti-TPO antibodies were determined by using the Roche Diagnostics COBAS Elecsys Anti‑TPO performed with a Cobas 6000 analyzer according to the manufacture’s instructions. Fasting blood glucose was measured by using an AU5800 Automatic Biochemical Analysis System (Beckman Coulter, CA, USA).

A cohort of 40 pregnant women who entered Shijiazhuang Obstetrics and Gynecology Hospital (Hebei, China) between March and October of 2018 were enrolled in this study. This cohort included 22 patients with GDM (diagnosed as described below) and 18 NDM controls. Women with pre-existing diabetes, impaired fasting glucose, chronic or serious acute infections, cardiovascular or hematological diseases, or abnormal liver or kidney function were excluded from the cohort. During the 24^th–28^th week of gestation, fasting plasma was collected and a 75-g, 3-hour oral glucose tolerance test (OGTT) was performed. Fasting plasma glucose was measured using an AU5800 Automatic Biochemical Analysis System (Beckman coulter, Brea, CA, USA). GDM was diagnosed according to the criteria of the International Association of Diabetes and Pregnancy Study Group (IADPSG)^{16 (link)}, with at least one plasma glucose level being no less than the following thresholds: fasting, 5.1 mmol/L, OGTT- 1 hour, 10.0 mmol/L, OGTT- 2 hour, 8.5 mmol/L. The study was conducted according to the guidelines in the Declaration of Helsinki and approved by the Ethics Committee of Shijiazhuang Obstetrics and Gynecology Hospital.